Cameron Sabet and Simar Bajaj April 27, 2023 1:34 p.m. A pharmacist delivers a Covid-19 booster shot in Chicago during a clinic for seniors. E. Jason Wambsgans / Chicago Tribune / Tribune News Service via Getty Images A trio of recent announcements have put Covid-19 vaccines and boosters back into the spotlight. On April 10, President...
By Jillian Wilson Sep 13, 2022, 10:55 AM EDT|Updated 3 hours ago As of Sept. 1, the Centers for Disease Control and Prevention authorized an updated COVID-19 vaccine with the goal of fending off a surge in cases this fall and winter. Moderna and Pfizer both have new bivalent vaccines that target the original strain of coronavirus and omicron subvariants...
by Noor Adatia Credit: Unsplash/CC0 Public Domain A spike in flu cases across the country, along with another COVID-19 surge, is leaving more people vulnerable to catching some form of disease—especially those who aren’t vaccinated. And although the flu is most common during the fall and winter, people remain susceptible to influenza year round, including...
by Emily Caldwell, The Ohio State University A COVID-19 booster shot will provide strong and broad antibody protection against the range of omicron sublineage variants of the SARS-CoV-2 virus in circulation, two new studies using serum from human blood samples suggest. Researchers tested neutralizing antibody levelsagainst the BA.2 and BA.3 omicron variants and deltacron, a recombinant variant created...
Credit: Pixabay/CC0 Public Domain Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company’s COVID-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would “allow for a fourth dose of our #COVID19 vaccine in adults 18 years of age...
Robert Towey@ROBERTTOWEYCNBC Dr. Ofer Levy, a voting member of the FDA’s vaccine advisory panel, spoke with CNBC’s “Closing Bell” after the committee unanimously recommended the agency approve J&J’s Covid boosters. The panel previously recommended the FDA approve boosters from Moderna and Pfizer for anyone 65 and older, among other high-risk groups. Some committee members have...
